Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

ArcPacific Announces Name Change and New Ticker Symbol

Newsfile May 10, 2023

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

GlobeNewswire April 17, 2023

BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created "SpinCo" Entity whereby Shareholders to Receive One New Share of "SpinCo" in Addition to Each Current Share of BriaCell Already Held

GlobeNewswire March 30, 2023

BriaCell (TSX:BCT) to present clinical and survival data with posters

Brieanna McCutcheon  March 15, 2023

BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting

GlobeNewswire March 15, 2023

BriaCell (TSX:BCT) reports positive survival data in advanced metastatic Breast Cancer

John Ballem  February 23, 2023

BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer

GlobeNewswire February 23, 2023

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

GlobeNewswire February 9, 2023

BriaCell CEO Letter to Shareholders

GlobeNewswire January 24, 2023

BriaCell to Investigate Alleged Illegal Trading of Public Securities

GlobeNewswire January 23, 2023

BriaCell (TSX:BCT) leaves FDA meeting for Phase II Bria-IMT combination in advanced metastatic breast cancer feeling positive

Brieanna McCutcheon  January 18, 2023

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer

GlobeNewswire January 18, 2023

BriaCell (TSX:BCT) receives new patent notification

Azuka Onwuka January 10, 2023

BriaCell Announces New Patent Issuance, Bria-OTS(TM) IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

GlobeNewswire January 10, 2023

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

TheNewsWire December 14, 2022

BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

Brieanna McCutcheon  December 8, 2022

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®

GlobeNewswire December 8, 2022

BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

TheNewsWire December 2, 2022

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

Business Wire November 30, 2022

BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com

GlobeNewswire November 15, 2022